Patients Europe News Today : Breaking News, Live Updates & Top Stories | Vimarsana

European Commission Approves Pfizer s ELREXFIO® for Relapsed and Refractory Multiple Myeloma -December 08, 2023 at 07:56 am EST

Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial ELREXFIO is an off-the-shelf ,.

United kingdomAl hamedChris boshoffMyeloma research foundationPfizer incExchange commissionHealthcare products regulatory agencyEnd results programDrug administrationApproval programCommittee for medicinal products human useNational cancer instituteEuropean medicines agencyEuropean commissionOncology researchWorld health organization

European Commission Approves Pfizer s ELREXFIO for Relapsed and Refractory Multiple Myeloma

08.12.2023 - Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory .

United kingdomAl hamedExchange commissionApproval programDrug administrationEuropean commissionNational cancer instituteMyeloma research foundationWorld health organizationEnd results programHealthcare products regulatory agencyEuropean medicines agencyCommittee for medicinal products human useMedicinal productsHuman useAccelerated approval program

Innovative cancer diagnostics must be seen as investment, says patient group chief

Innovative cancer diagnostics must be seen as investment, says patient group chief
euractiv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euractiv.com Daily Mail and Mail on Sunday newspapers.

United kingdomAntonella cardoneEuropean commissionCancer cell internationalEuropean unionCancer patients europePatients europeEastern europeanWestern europeCommission president ursulaCancer planBeating cancer plan

24% of patients will wait 5 months or more to get a myeloma diagnosis

24% of patients will wait 5 months or more to get a myeloma diagnosis Brussels, 27 September 2023 – Today is European Myeloma Day, a date to raise awareness about the most important issues for European myeloma patients. The findings of a recent report developed by Myeloma Patients Europe (MPE) are the dri.

Bruxelles capitalePaula rochaVince clausLise lott erikssonKatie joynerKate morganEuropean myeloma dayMyeloma patients europeMyeloma diagnosis pathwayCo chief executive officerDiagnosis pathwayMyeloma diagnosis across europeDiagnosis experiencesEuropean myeloma patientsand perspectivesLott erikssonChief executive officer

Burgeoning Immunotherapy Options in Oncology Move Beyond CAR T and the Usual Disease States

The use of immune therapies for hematological malignancies is expanding beyond chimeric antigen receptor (CAR) T-cell therapies in the traditional lymphoid disease states, but the impact on patient quality of life must remain top of mind, according to speakers at the European Hematology Association 2023 Congress.

Hermann einseleHans scheurerKarolinska institutetEmma morrisStephan mielkeWorkgroup of european cancer patient advocacy networksUniversity college londonEuropean hematology associationProfessor emma morrisUniversity collegeProfessor stephan mielkeEuropean cancer patient advocacyPatients europe